pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2519Research ArticleОБЗОРЫREVIEWПреимущества порошковой ингаляционной системы HandiHaler® при лечении хронической обструктивной болезни легких различной тяжестиAdvantages of powdered inhalation system HandiHaler® in therapy of chronic obstructive pulmonary diseaseЛещенкоИ. В.LeschenkoI. V.
Екатеринбург
БарановаИ. И.BaranovaI. I.
Екатеринбург
Уральская государственная медицинская академияRussian FederationКлиника пульмонологии МО "Новая больница"Russian Federation20041708202104124127Copyright © Лещенко И.В., Баранова И.И., 20212021Лещенко И.В., Баранова И.И.Leschenko I.V., Baranova I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2519
.
.
ReferencesGlobal initiative for chronic obstructive pulmonary disease (GOLD). Global strategy for the diagnosis, management, and prévention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Publ. № 2701. April 2001.Global initiative for chronic obstructive pulmonary disease (GOLD). Global strategy for the diagnosis, management, and prévention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Publ. № 2701. April 2001.Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute. April 2001; Update of the management sections, GOLD web-site (www.goldcopd.com ). Date update: 1 Jule 2003.Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute. April 2001; Update of the management sections, GOLD web-site (www.goldcopd.com ). Date update: 1 Jule 2003.Witek T.J., Schachter E.N. Delivery of drugs by aerosol. In Pharm acology and therapeutics in respiratory care. Philadelphia: Saunders; 1994: 31-55.Witek T.J., Schachter E.N. Delivery of drugs by aerosol. In Pharm acology and therapeutics in respiratory care. Philadelphia: Saunders; 1994: 31-55.National Heart, Lung and Blood Institute, National Institutes of Health. International consensus reports on diagnosis and treatment of asthma. Eur. Respir. J. 1992; 5: 601-641.National Heart, Lung and Blood Institute, National Institutes of Health. International consensus reports on diagnosis and treatment of asthma. Eur. Respir. J. 1992; 5: 601-641.Larsen J.S., Hahn М., Ekholm B., Wick K.A. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J. Asthma 1994; 31: 193-199.Larsen J.S., Hahn М., Ekholm B., Wick K.A. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J. Asthma 1994; 31: 193-199.Thomson J., Irvine T.N., Grathwohl K., Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest 1994; 105: 715-717.Thomson J., Irvine T.N., Grathwohl K., Roth B. Misuse of metered-dose inhalers in hospitalized patients. Chest 1994; 105: 715-717.Hanania N.A., W ittman R., Kesten S., Chapman K.R. Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers and breath-actuated dry powder inhalers. Chest 1994; 105: 111-117.Hanania N.A., W ittman R., Kesten S., Chapman K.R. Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers and breath-actuated dry powder inhalers. Chest 1994; 105: 111-117.Kallen. Bricanyl Turbuhaler® in the treatment of asthma: a six week multi-centre study carried out in Sweden, the United Kingdom, Denmark, Norway and Finland. Eur. Respir. J. 1991; 4: 175-179.Kallen. Bricanyl Turbuhaler® in the treatment of asthma: a six week multi-centre study carried out in Sweden, the United Kingdom, Denmark, Norway and Finland. Eur. Respir. J. 1991; 4: 175-179.Kesten S., Elias М., Girling W. et al. Patient handing of a multi-dose dry powder inhalation device for albuterol. Chest 1994; 105: 1077-1081.Kesten S., Elias М., Girling W. et al. Patient handing of a multi-dose dry powder inhalation device for albuterol. Chest 1994; 105: 1077-1081.Chrystyn H. The discus inhaler. A review of its pharmaceutical and clinical performance. Clin. D ru g Invest. 1999; 18: 403-412.Chrystyn H. The discus inhaler. A review of its pharmaceutical and clinical performance. Clin. D ru g Invest. 1999; 18: 403-412.Srichana T ., Martin G.P., Marrio tt C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm . Sci. 1998; 7: 73-80.Srichana T ., Martin G.P., Marrio tt C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm . Sci. 1998; 7: 73-80.Borgstom L.E., Bondesson F., Moren E. et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subject. Eur. Respir. J. 1994; 7: 69 -73.Borgstom L.E., Bondesson F., Moren E. et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subject. Eur. Respir. J. 1994; 7: 69 -73.Malton A ., Sumby B .S., Dandiker Y. A comparison of in vitro drug delivery from salbutamol Diskus and terbutaline Turbuhale inhalers. J. Pharm. Med. 1996; 6: 35-48.Malton A ., Sumby B .S., Dandiker Y. A comparison of in vitro drug delivery from salbutamol Diskus and terbutaline Turbuhale inhalers. J. Pharm. Med. 1996; 6: 35-48.Dewar M.H., Jamieson A., McLean A., Crompton G.K. Peak inspiratory flow through Turbuhaler in chronic obstructive airway disease. Respir. Med. 1999; 93: 342-344.Dewar M.H., Jamieson A., McLean A., Crompton G.K. Peak inspiratory flow through Turbuhaler in chronic obstructive airway disease. Respir. Med. 1999; 93: 342-344.Hill L.S., Slater A.L. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir. Med. 1998; 92: 105-110.Hill L.S., Slater A.L. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir. Med. 1998; 92: 105-110.Barnes P.J. The pharmacological properties of tiotropium Chest 2000; 117: 63S-66S.Barnes P.J. The pharmacological properties of tiotropium Chest 2000; 117: 63S-66S.Chodosh S., Flanders J. S., Kesten S. et al. Effective delivery of particles with the HandiHalere dry powder inhalation system over a range of Chronic Obstructive Pulmonary Disease Severity. J. Aerosol Med. 2001; 14 (3): 309-315.Chodosh S., Flanders J. S., Kesten S. et al. Effective delivery of particles with the HandiHalere dry powder inhalation system over a range of Chronic Obstructive Pulmonary Disease Severity. J. Aerosol Med. 2001; 14 (3): 309-315.Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspirotary conditions in healthy volunteers — implication for in vitro testing. J. Aerosol Med. 1993; 6: 99-110.Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspirotary conditions in healthy volunteers — implication for in vitro testing. J. Aerosol Med. 1993; 6: 99-110.Richards R., Saunders M. Need for a comparative performance standard for dry powder inhalers. Thorax 1993; 48: 1186-1187.Richards R., Saunders M. Need for a comparative performance standard for dry powder inhalers. Thorax 1993; 48: 1186-1187.Svartengren K., Lindstad P.-A., Svartengren M. et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med. 1995; 152: 32-37.Svartengren K., Lindstad P.-A., Svartengren M. et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med. 1995; 152: 32-37.Dahl R., Backer V., Ollgaard B. et al. Assessment of patient performance of the HandiHalera compared with the metered dose inhaler four weeks after instruction. Respir. Med. 2003; 97: 1126-1133.Dahl R., Backer V., Ollgaard B. et al. Assessment of patient performance of the HandiHalera compared with the metered dose inhaler four weeks after instruction. Respir. Med. 2003; 97: 1126-1133.
The authors declare that there are no conflicts of interest present.